Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy
The incidence rate of prostate cancer is higher in male cancers. With a hidden initiation of disease and long duration, prostate cancer seriously affects men’s physical and mental health. Prostate cancer is initially androgen-dependent, and endocrine therapy can achieve good results. However, after...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/4/967 |
| _version_ | 1797482053952864256 |
|---|---|
| author | Yao Jiang Weihong Wen Fa Yang Donghui Han Wuhe Zhang Weijun Qin |
| author_facet | Yao Jiang Weihong Wen Fa Yang Donghui Han Wuhe Zhang Weijun Qin |
| author_sort | Yao Jiang |
| collection | DOAJ |
| description | The incidence rate of prostate cancer is higher in male cancers. With a hidden initiation of disease and long duration, prostate cancer seriously affects men’s physical and mental health. Prostate cancer is initially androgen-dependent, and endocrine therapy can achieve good results. However, after 18–24 months of endocrine therapy, most patients eventually develop castration-resistant prostate cancer (CRPC), which becomes metastatic castration resistant prostate cancer (mCRPC) that is difficult to treat. Chimeric Antigen Receptor T cell (CAR-T) therapy is an emerging immune cell therapy that brings hope to cancer patients. CAR-T has shown considerable advantages in the treatment of hematologic tumors. However, there are still obstacles to CAR-T treatment of solid tumors because the physical barrier and the tumor microenvironment inhibit the function of CAR-T cells. In this article, we review the progress of CAR-T therapy in the treatment of prostate cancer and discuss the prospects and challenges of armed CAR-T and combined treatment strategies. At present, there are still many obstacles in the treatment of prostate cancer with CAR-T, but when these obstacles are solved, CAR-T cells can become a favorable weapon for the treatment of prostate cancer. |
| first_indexed | 2024-03-09T22:23:48Z |
| format | Article |
| id | doaj.art-18344fb069f64873821b6cafdae09bfa |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T22:23:48Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-18344fb069f64873821b6cafdae09bfa2023-11-23T19:09:17ZengMDPI AGCancers2072-66942022-02-0114496710.3390/cancers14040967Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination TherapyYao Jiang0Weihong Wen1Fa Yang2Donghui Han3Wuhe Zhang4Weijun Qin5Department of Urology, First Affiliated Hospital of Air Force Military Medical University, Xi’an 710032, ChinaDepartment of Medical Research, Northwestern Polytechnical University, Xi’an 710072, ChinaDepartment of Urology, First Affiliated Hospital of Air Force Military Medical University, Xi’an 710032, ChinaDepartment of Urology, First Affiliated Hospital of Air Force Military Medical University, Xi’an 710032, ChinaDepartment of Urology, Air Force 986 Hospital, Xi’an 710054, ChinaDepartment of Urology, First Affiliated Hospital of Air Force Military Medical University, Xi’an 710032, ChinaThe incidence rate of prostate cancer is higher in male cancers. With a hidden initiation of disease and long duration, prostate cancer seriously affects men’s physical and mental health. Prostate cancer is initially androgen-dependent, and endocrine therapy can achieve good results. However, after 18–24 months of endocrine therapy, most patients eventually develop castration-resistant prostate cancer (CRPC), which becomes metastatic castration resistant prostate cancer (mCRPC) that is difficult to treat. Chimeric Antigen Receptor T cell (CAR-T) therapy is an emerging immune cell therapy that brings hope to cancer patients. CAR-T has shown considerable advantages in the treatment of hematologic tumors. However, there are still obstacles to CAR-T treatment of solid tumors because the physical barrier and the tumor microenvironment inhibit the function of CAR-T cells. In this article, we review the progress of CAR-T therapy in the treatment of prostate cancer and discuss the prospects and challenges of armed CAR-T and combined treatment strategies. At present, there are still many obstacles in the treatment of prostate cancer with CAR-T, but when these obstacles are solved, CAR-T cells can become a favorable weapon for the treatment of prostate cancer.https://www.mdpi.com/2072-6694/14/4/967CAR-T cell therapyimmunotherapyprostate canceranti-PD-L1checkpoint inhibitor |
| spellingShingle | Yao Jiang Weihong Wen Fa Yang Donghui Han Wuhe Zhang Weijun Qin Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy Cancers CAR-T cell therapy immunotherapy prostate cancer anti-PD-L1 checkpoint inhibitor |
| title | Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy |
| title_full | Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy |
| title_fullStr | Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy |
| title_full_unstemmed | Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy |
| title_short | Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy |
| title_sort | prospect of prostate cancer treatment armed car t or combination therapy |
| topic | CAR-T cell therapy immunotherapy prostate cancer anti-PD-L1 checkpoint inhibitor |
| url | https://www.mdpi.com/2072-6694/14/4/967 |
| work_keys_str_mv | AT yaojiang prospectofprostatecancertreatmentarmedcartorcombinationtherapy AT weihongwen prospectofprostatecancertreatmentarmedcartorcombinationtherapy AT fayang prospectofprostatecancertreatmentarmedcartorcombinationtherapy AT donghuihan prospectofprostatecancertreatmentarmedcartorcombinationtherapy AT wuhezhang prospectofprostatecancertreatmentarmedcartorcombinationtherapy AT weijunqin prospectofprostatecancertreatmentarmedcartorcombinationtherapy |